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Summary. The striatum receives the majority of excitatory amino acidergic input 
to the basal ganglia from neocortical and allocortical sources. The subthalamic 
nucleus and the substantia nigra also receive excitatory amino acidergic inputs 
from neocortex. The subthalamic nucleus, which has prominent projections to 
the pallidum and nigra, is the only known intrinsic excitatory amino acidergic 
component of the basal ganglia. Possible excitatory amino acidergic inputs reach 
the basal ganglia from the intralaminar thalamic nuclei and the pedunculo- 
pontine nucleus. The striatum is richly endowed with all subtypes of excitatory 
amino acid receptors and these appear to be inhomogeneously distributed 
within the striatal complex. The non-striatal nuclei contain lesser levels of 
excitatory amino acid receptors and the relative proportion of these receptors 
varies between nuclei. The presence of high densities of excitatory amino acid 
receptors is a phylogenetically conserved feature of the striatum and its non- 
mammalian homologues. In Huntington's disease, there is substantial depletion 
of e-amino-3-hydroxy-5-methylisoxazole-4-propionic acid, N-methyl-D-aspar- 
tate, and kainate receptors within the striatum. In Parkinson's disease substantia 
nigra, there is significant loss of N-methyl-D-aspartate and e-amino-3-hydroxy- 
5-methylisoxazole-4-propionic acid receptors. 
Keywords: Amino acids - Glutamate - Aspartate - ~-Amino-3-hydroxy-5- 
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Introduction 
Excitatory amino acids (EAAs) are the predominant excitatory neurotrans- 
mitter(s) within the central nervous system. Their function(s) have, therefore, 
become a central issue in contemporary neurobiology. While considerable re- 
search has focused on such cytoarchitectonically simple regions as the hippo- 
campus, the cerebellum, and the spinal cord, the role of EAAs in more complex 
regions of the neocortex and basal ganglia is now being explored. In this article 
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we review the organization of EAAergic pathways involving the basal ganglia, 
the distribution of EAA binding sites within the basal ganglia, the comparative 
anatomy of EAA binding site distribution within the striatopallidal complex, 
and changes in EAA binding sites in human basal ganglia diseases. 
EAAergic pathways involving the basal ganglia 
The best characterized EAAergic pathway involving the basal ganglia is the 
massive neocorticostriate projection (Fig. 1). Data from biochemical (Fonnum 
et al., 1981; Girault et al., 1986; Godukhin et al., 1980; Hassler et al., 1982; 
McGeer et al., 1977), electrophysiological (Herrling, 1985; Spencer, 1976; Stone, 
1979), immunocytochemical (Dinopoulos et al., 1989), and [3H]D-aspartate 
tracing studies (Streit, 1980) leads to the conclusion that EAAs are the primary 
neurotransmitter of neocorticostriate neurons. The anatomy of this projection 
appears to be complex. While it is clear that the neocorticostriate projection has 
a topographic character (Kemp and Powell, 1970; McGeorge and Faull, 1989), 
it is now known that cortical projections to the so-called 'patch' and 'matrix' 
components of the striatum differ in terms of regional and laminar origin 
(Donoghue and Herkenham, 1986; Gerfen, 1989). Most studies of neocorti- 
costriate projection anatomy have been done in rat brain and there are indica- 
tions that the organization of neocorticostriate projections is more complicated 
in animals with more differentiated cortices (Tanaka, 1987; Selemon and Rakic, 
1985). 
Just as the striatum proper receives massive EAAergic innervation from the 
neocortex, the ventral portions of the striatal complex, the nucleus accumbens 
and olfactory tubercule, receive innervation from neocortical regions but also 
from limbic, allocortical regions including the subiculum of the hippocampal 
formation, the basolateral nucleus of the amygdala, and the primary olfactory 
cortex (Fig. 1) (McGeorge and Faull, 1989). While studies directed at identifying 
the neurotransmitter of these allocortical striatal afferents are limited, the avail- 
able evidence indicates that EAAs are the primary neurotransmitters of these 
pathways (Robinson and Beart, 1988; Christie et al., 1985a; Walaas, 1981; 
Walaas and F0nnum, 1979; Fuller et al., 1987). 
Two other basal ganglia nuclei receive neocortical input (Fig. 1). The sub- 
thalamic nucleus is the target of a well characterized projection from frontal 
cortex (Afsharpour, 1985). Afsharpour (1985) has suggested that subthalamic 
nucleus afferents from the neocortex may be collaterals of corticobulbar and 
corticospinal neurons. Electrophysiological evidence indicates that this projec- 
tion is EAAergic and acts through non-N-methyl-D-aspartate receptors 
(Rouzaire-Dubois and Scarnati, 1987b; Rouzaire-Dubois and Scarnati, 1987a). 
The substantia nigra also receives afferents from neocortex. Both retrograde and 
anterograde tracing studies indicate the presence of a neocortico-nigral pathway 
that appears to terminate mainly on dopaminergic neurons (Beckstead, 1979; 
Bunney and Aghajanian, 1976), and biochemical evidence suggests that this 
pathway is EAAergic (Kornhuber et al., 1985; Christie et al., 1985b). 
The only intrinsic portion of the basal ganglia that uses EAAs as a neuro- 
transmitter is the subthalamic nucleus (STN). While the STN was thought for 









Fig. 1. Excitatory amino acidergic pathways involving the basal ganglia of the rat. 
(A) Confirmed excitatory amino acidergic afferents of the basal ganglia. (B) Projections of the 
subthalamic nucleus. The striatal efferent is represented as a dashed line to indicate that it 
is a weak projection in rats but may be more substantial in other mammals. (C) Possible 
excitatory amino acidergic afferents to the basal ganglia. C X T  neocortex, PO primary 
olfactory cortex, H I P  hippocampus, SUB subiculum, S T R  dorsal striatum, ACC nucleus 
accumbens, O T olfactory tubercule, GP globus pallidus, VP ventral pallidum, EP ento- 
peduncular nucleus, S T N  subthalamic nucleus, SNc substantia nigra pars compacta, 
SNr substantia nigra pars reticulata, I L T  intralaminar/midline thalamic nuclei, 
A M  amygdala, PPn pedunculopontine nucleus 
some years to be GABAergic, recent electrophysiological, biochemical, and 
immunocytochemical evidence indicates that this nucleus is EAAergic (Albin et 
al., 1989a; Mitchell et al., 1991; Robledo and Feger, 1990). The STN has promi- 
nent projections (Fig. 1) to the globus pallidus (lateral segment of the globus 
pallidus in primates), the ventral pallidum, the entopeduncular nucleus (medial 
segment of the globus pallidus in primates), and substantia nigra (including both 
the pars compacta and pars reticulata) (Kita and Kitai, 1987; Groenewegen and 
Berendse, 1990). There are also reciprocal connections between the STN and 
striatum which appear to be quantitatively small in rodents but may be larger 
in carnivores and primates (Beckstead, 1983; Parent  et al., 1989; Fig. 1). 
There are possibly two additional EAAergic afferents to the basal ganglia 
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(Fig. 1). The intralaminar/midline nuclei project to the striatal complex, the 
globus pallidus, the ventral pallidum, and the STN (Parent, 1990). Retrograde 
[3H]D-aspartate tracing studies indicate that some components of the 
intralaminar/midline complex have an EAAergic projection to the striatum 
(Fuller et al., 1987). However; Nieoullon and colleagues (1985) have shown that 
biochemical indices of EAAergic function in the striatum do not decrease after 
lesions of the parafascicular nucleus, a portion of the midline complex with 
prominent striatal efferents. No other neurotransmitter has been identified with- 
in parafascicular nucleus neurons and these discrepant findings await resolution. 
The pedunculopontine nucleus (PPN) is another possibly EAAergic afferent of 
the basal ganglia. The PPN innervates the substantia nigra, the globus pallidus, 
and entopeduncular nucleus (Parent, 1990). The PPN appears to contain a 
mixed population of cholinergic and non-cholinergic neurons (Rye et al., 1987). 
Butcher and colleagues have suggested that the PPN sends cholinergic efferents 
to its basal ganglia targets (Gould et al., 1989). Lee et al. (1988), however, have 
found that the non-cholinergic neurons of the PPN tend to innervate basal 
ganglia structures while cholinergic PPN neurons tend to innervate the 
thalamus. The findings of Lee et al. (1988) are consistent with the results of 
Scarnati et al. (1986), who found that PPN induced excitation of nigral neurons is 
not blocked by scopolamine. While this leaves open the possibility that PPN 
excitatory neurotransmission might be mediated by nicotinic cholinergic recep- 
tors, Scarnati et al. (1986) also found that PPN excitation of the nigra was 
blocked by EAA antagonists. The findings of Scarnati et al. (1986) are consistent 
with the existence of EAAergic PPN neurons but further work must be done to 
identify the neurotransmitter of PPN neurons innervating the basal ganglia. 
EAA receptors within the basal ganglia 
In common with other classes of neurotransmitter receptors, EAAs exert their 
effects via receptor subtypes with distinctive physiologic and pharmacologic 
properties. There are presently four generally accepted and well defined subtypes 
of post-synaptic EAA receptor (Monaghan et al., 1989; Young and Fagg, 1990). 
Three of these receptors are ionotropic receptors and are named after their 
prototype agonists. The e-amino-3-hydroxy-5-methylisoxazole-4-propionic ac- 
id (AMPA) and kainate (KA) receptors form ligand gated ion channels perme- 
ated by monovalent cations and mediate conventional fast neurotransmission. 
The N-methyl-D-aspartate (NMDA) receptor has unusual properties. It is 
permeated by both Ca ++ and monovalent cations, produces a post-synaptic 
potential with long latency of onset and prolonged duration, exhibits voltage 
dependent activation, and possesses additional modulatory sites for glycine, 
polyamines, and phencyclidine ligands. Activation of NMDA receptors is 
thought to underlie some forms of synaptic plasticity. EAAs also activate 
a non-ionotropic (metabotropic; MET) receptor that stimulates inositol 
phospholipid turnover (Sladeczek et al., 1988). In addition to these well defined 
receptors, we have described an [3H]glutamate binding site that is insensitive 
to displacement with KA, quisqualate (eliminating both AMPA and MET 
binding sites), or NMDA. The physiologic identity of this non-NMDA, non-KA, 
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non-quisqualate (NNKQ) binding site is unknown, but lesion experiments indi- 
cate that it is located on striatal neurons (Higgins et al., 1989; Greenamyre et 
al., 1990). 
We have used receptor autoradiography to systematically study the distribu- 
tion of EAA binding sites in rat basal ganglia (Albin et al., 1991). All assays were 
done with single concentrations of ligand, and we have assumed that the affinity 
of binding sites for ligand(s) are invariant from region to region. Tritiated KA 
and AMPA were used to assay KA and AMPA binding sites. To assay NMDA 
and MET binding sites, we used [3H]glutamate under selective conditions. 
EAA binding sites were found to be distributed heterogeneously within the 
striatal complex and between non-striatal basal ganglia nuclei (Table 1, Fig. 2). 
Within the striatal complex, there was a high level of all EAA binding site 
subtypes. KA binding sites had a significantly higher level in the lateral portion 
of the dorsal striatum than in the medial portion of the dorsal striatum. NMDA 
and AMPA binding sites had significantly higher levels in the ventral (nucleus 
accumbens and olfactory tubercule) portion of the striatal complex than in the 
dorsal striatum. No other medial-lateral or dorsal-ventral gradients of EAA 
binding sites were noted within the striatal complex. While we did not find any 
medial-lateral differences in NMDA binding site distribution within the striatal 
complex, Monaghan et al. (1988) have found evidence of NMDA binding site 
inhomogeneity within the dorsal striatum. Specifically, they have suggested that 
the NMDA binding site exists in either agonist or antagonist preferring confor- 
mations and that the relative proportion of these conformations differs between 
medial and lateral dorsal striatum. The available evidence suggests that the 
majority of striatal EAA binding sites are post-synaptic though some evidence 
indicates the presence of pre-synaptic EAA receptors on nigrostriatal 
dopaminergic terminals and on corticostriate terminals (Greenamyre and 
Young, 1989; Errami and Nieoullon, 1988; Cheramy et al., 1986). 
To assess the relative distribution of EAA binding site subtypes between the 
non-striatal nuclei of the basal ganglia, we normalized the level of each EAA 
binding site subtype by expressing levels of EAA binding site subtypes in each 
non-striatal nucleus as a percentage of striatal binding levels (Table 1). These 
percentages were compared with one way analysis of variance to assess the 
relative level of each EAA binding site subtype within the nonstriatal nuclei of 
the basal ganglia. All EAA binding site subtypes were found within all non- 
striatal nuclei but the level of all EAA binding site subtypes was lower in the 
non-striatal nuclei than in the striatal complex. The level of the NMDA binding 
site subtype was particularly low in all non-striatal nuclei. AMPA and MET 
binding sites had relatively higher levels in the globus pallidus, ventral pallidum, 
and subthalamic nucleus. MET binding sites had relatively high levels in the 
entopeduncular nucleus and substantia nigra (includes both pars compacta and 
pars reticulata), and N N K Q  binding sites had relatively high levels in the globus 
pallidus, ventral pallidum, entopeduncular nucleus, and nigra. KA binding sites 
had a relatively high level in the ventral pallidum, subthalamic nucleus, and 
entopeduncular nucleus. Our results provide evidence of significant heterogene- 
ity of distribution of EAA binding site subtypes within the basal ganglia and 
indicate that the actions of EAAs within the various nuclei of the basal ganglia 
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Table 1. Density of excitatory amino acid binding sites in rat basal 
ganglia. Units are pmol/mg prot (S.E.M.). Percentages are percent of 
binding in region as percentage of binding in the striatal complex" 
Region NMDA AMPA MET KA NNKQ 
Lateral 0.673 2.417 0.694 1 .0041  1.513 
Striatum b (0.016) (0.031) (0.053) (0.172) (0.193) 
Medial 0.676 2.559 0.738 0.958 1.493 
Striatum b (0.06) (0.082) (0.076) (0.179) (0.140) 
Dorsal 0.68 2.287 0.734 0.894 1.500 
Striatum c (0.016) (0.105) (0.035) (0.091) (0.167) 
Nucleus 1.002 2.712 0.767 0.9843 1.527 
Accumbens (0.039) (0.286) (0.084) (0.091) (0.133) 
Olfactory 1.25 2.583 0.834 1.015 1.373 
Tubercule (0.063) (0.322) (0.093) (0.093) (0.140) 
Ventral 1.1272 2.6662 0.818 0.997 1.427 
Striatum d (0.031) (0.309) (0.086) (0.086) (0.133) 
Striatal 0.903 2.467 0.772 0.975 1.500 
Complex 
Globus 0.081 0.6263 0.1813 0.138 0.5333 
Pallidus (0.012) (0.054) (0.03) (0.01) (0.060) 
9~  25~ 23~ 14~ 36~ 
Ventral 0.173 0.8643 0.3633 0.4433 0.7403 
PaUidum (0.033) (0.036) (0.045) (0.030) (0.087) 
19~o 35~ 47~ 45~ 49~ 
Entopeduncular 0.064 0.41 0.1593 0.2333 0.2803 
Nucleus (0.006) (0.010) (0.030) (0.037) (0.027) 
7~ 16~ 21~ 23~ 19~o 
Subthalamic 0.161 0.778 0.3773 0.285 0.223 
Nucleus (0.015) (0.051) (0.059) (0.042) (0.053) 
18~ 31~o 49~ 29~ 15~ 
Substantia 0.112 0.578 0.2593 0.193 0.6133 
Nigra (0.014) (0.025) (0.038) (0.042) (0.040) 
12~o 23~ 34~o 20~o 41~ 
Ventral 0.188 0.450 0.11 0.148 0.360 
Tegmental Area (0.031) (0.030) (0.051) (0.047) (0.053) 
20~0 18~ 14~o 15~o 24~o 
" mean of dorsal striatum, accumbens, and olfactory tubercule weighted 
to correct extent of dorsal striatum 
b medial and lateral striatum measurements from animals sectioned in 
coronal plane 
c mean of lateral and medial striatum in coronal sections averaged with 
STR from parasagittal sections 
d mean of nucleus accumbens and olfactory tubercule 
1 lateral greater than medial by paired t-test 
2 ventral greater than dorsal striatum by paired t-test 
3 relatively higher level of binding for superscripted binding sites than 
binding sites without superscripts by one way analysis of variance of 
percentage of complex binding 
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Fig. 2. Parasagittal autoradiographs of excitatory amino acid binding sites in the basal 
ganglia of the rat. (A) NMDA. (B) AMPA. (C) KA. (D) MET; image made by digital 
subtraction of nonspecific binding from total binding on adjacent sections. (E) NNKQ. 
STR dorsal striatum, ACC nucleus accumbens, O T olfactory tubercule, VP ventral pallidum, 
GP globus pallidus, STN subthalamic nucleus, SN substantia nigra. Magnification of 10x 
prior to reduction 
is likely to be complex. Our discovery of heterogeneous distiibution of basal 
ganglia EAA binding sites probably only hints at the complexity of EAA receptor 
distribution in the basal ganglia. Molecular cloning studies have shown multiple 
isoforms of the AMPA receptor and it is likely that multiple isoforms of other 
EAA receptors will eventually be identified. It would not be surprising if there 
is a heterogeneous distribution of receptor subtype isoforms between and within 
the different nuclei of the basal ganglia. 
The finding that non-NMDA receptors predominate in the non-striatal 
nuclei of the basal ganglia has implications for the clinical pharmacology of 
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Parkinson's disease (PD). A considerable body of evidence indicates that 
hyperactivity of the subthalamic nucleus and consequent excessive excitation of 
the pallidum and nigra is an important component of the pathophysiology of 
PD (Albin et al., 1989b). Blockade of the cortical input to the subthalamic 
nucleus would decrease the activity of the subthalamic nucleus, pallidum, and 
nigra. A similar effect could be achieved by blocking the effect of the subthalamic 
nucleus on the pallidum and nigra. Blockade of non-NMDA EAA receptors in 
the subthalamic nucleus, pallidum, and nigra might restore the activity of these 
nuclei towards normal levels. The pharmacology of non-NMDA EAA antag- 
onists is an expanding field and non-NMDA EAA antagonists may prove 
useful in the symptomatic treatment of PD. 
The comparative anatomy of EAA receptors in the striatopailidal complex 
It is now generally appreciated that the striatopallidal complex is one of the 
oldest and most conserved portions of the forebrain. Northcutt (1981) has 
suggested that a homologue of the striatum was present in all early ancestral 
vertebrates, and several lines of evidence indicate that a homologue of the 
striatum is found in many modern vertebrates (Parent, 1986). Among amniotic 
vertebrates (those possessing an amniotic membrane; reptiles, avians, and 
mammals), the degree of homology is particularly marked. The hodology, 
histochemistry, neurotransmitter content, and neuropeptide content of the 
striatal, pallidal, and nigral homologues exhibit striking similarities in mammals, 
avians, and reptiles (Reiner and Anderson, 1990; Reiner et al., 1984). Recent 
studies of receptor distribution in non-mammalian vertebrates have confirmed 
the marked degree of similarity of the striato-pallidal complex of amniotic 
vertebrates. Dietl et al. (1988a; 1988b; 1988c) have studied the distribution of 
muscarinic cholinergic, dopamine, and GABA/benzodiazepine receptors in pi- 
geon (Columba livia) striatopallidal complex and found the distribution of these 
binding sites to be identical with those seen in mammals. The distribution of 
benzodiazepine and muscarinic cholinergic binding sites in turtle (Pseudemys 
scripta) forebrain Shows a pattern of binding in the striatopallidal homologue 
similar to that seen in mammals and avians (Schlegel and Kriegstein, 1987). 
We have examined the distribution and pharmacology of some EAA binding 
site subtypes in turtle and pigeon brain. We have concentrated on NMDA 
binding and characterized the NMDA binding site using both [3H]glutamate 
binding under selective conditions and the non-competitive NMDA ligand, 
[3H]MK-801 (Sakurai et al., 1990; Young et al., 1990). Our studies indicate that 
in both pigeon and turtle brain, NMDA binding sites possess properties similar 
to those found in mammalian brain. In the striatopallidal complex of both 
pigeons and turtles (Fig. 3), the pattern of distribution of NMDA binding sites 
was similar to that seen in mammals, i.e., high levels of NMDA binding sites in 
the striatal homologue and lower levels in the pallidal homologue. We have 
obtained similar results with assays for KA binding sites and quisqualate binding 
sites (a combination of both AMPA and MET binding sites), though we have 
not extensively characterized the properties of these assays in either pigeon or 
turtle brain (Young et al., 1990; Richfield et al., 1988). 
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Fig. 3. Autoradiographs of NMDA binding sites in the striatopallidal homologues of pigeon 
(A) and turtle (B). (A) Pigeon: Right side is [3HIMK-801 binding and left-side is NMDA- 
displaceable [3H]glutamate binding. PA paleostriatum augmentatum (homologue of stri- 
atum in pigeon). PP paleostriatum primitivum (homologue of globus pallidus in pigeon). 
(B) Turtle: (1) NMDA-displaceable [3H]glutamate binding, (2) strychnine-insensitive 
[3H]glycine binding, (3) [3H]MK-801 binding, pa paleostriatum augmentatum 
EAA receptors in human basal ganglia disease 
Interest in the role of EAA receptors in human basal ganglia disease has been 
driven by the possibility that EAA receptors in general, and the NMDA receptor 
in particular, may be mediators of neuronal death in human neurodegenerative 
diseases. This idea remains the most popular hypothesis to explain the patho- 
genesis of Huntington's disease (HD; DiFiglia, 1990). Recent reports that 
NMDA antagonists block both MPTP (Turski et al., 1991) and amphetamine 
induced (Sonsalla et al., 1989) lesions of the nigrostriatal dopaminergic pathway 
raises the possibility that NMDA receptors may be involved in the pathogenesis 
of Parkinson's disease (PD). 
To explore the potential role of EAA receptors in the pathogenesis of HD 
and PD we have investigated the alterations in EAA binding sites in HD striatum 
and PD substantia nigra. In HD, we have studied the striatum of controls and 
HD victims with a variety of assays for EAA receptor subtypes. In the most 
recent study, adjacent sections from fourteen HD and twelve control brains were 
assayed for AMPA, KA, NMDA, and MET binding sites (Dure et al., 1991). In 
HD striatum, the level of all binding sites was reduced (Fig. 4). KA, AMPA, and 
NMDA binding sites were significantly reduced by fifty to sixty percent com- 
pared to controls while MET binding was reduced by thirty-one percent and 
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Fig. 4. Autoradiographs of AMPA binding in human control (C) and Huntington's disease 
striatum (HD). The amount of binding in HD striatum is reduced and the pattern of ligand 
binding has become quite inhomogeneous 
NNKQ binding sites were reduced by twenty-six percent. The reductions in 
MET and NNKQ binding were not statistically significant. The pattern of 
binding site loss was striking in that there was clear inhomogeneity of binding 
site loss within the striatum (Fig. 4). Parallel study of EAA binding sites within 
neocortex revealed no differences between HD and control brains. Our results 
are consistent with the hypothesis that EAA receptors mediate neuronal death 
in HD but do not provide unequivocal evidence that one EAA receptor subtype 
is more likely to be important than another in mediating neuronal death. 
NMDA, AMPA, MET, and NNKQ binding sites were measured in PD 
substantia nigra (Penney et al., 1990). As expected from animal studies, the level 
of binding was relatively low in substantia nigra. NMDA binding sites were 
significantly reduced in the pars compacta and pars reticulata of PD brains 
~ompared to controls while AMPA and NNKQ binding sites were reduced in 
the pars compacta and MET binding sites were unchanged in either pars 
compacta or pars reticulata. At very least, these results suggest that NMDA, 
AMPA, and NNKQ binding sites are located on dopaminergic substantia nigra 
neurons. This inference is consistent with data suggesting that EAA receptors 
are located on nigral dopaminergic neurons and may be involved in regulating 
the activity of dopaminergic neurons (Mount et al., 1990; Araneda and Bustos, 
1989; Kalivas et al., 1989). These results are also consistent with a putative role 
for EAA receptors in mediating neuronal death in PD. As with HD, this data 
does not provide unequivocal evidence that an EAA mediated process is in- 
volved in the pathogenesis of HD. 
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